Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481740 | 0.83 | AR (0.48) | ARNR3C1PGR | |
| SCHEMBL5122217 | 0.80 | AR (1.00) | ARNR3C1PGR | |
| SCHEMBL6306983 | 0.74 | AR (0.50) | ARNR3C1 | |
| SCHEMBL6308099 | 0.73 | AR (0.90) | ARNR3C1PGR | |
| SCHEMBL3023968 | 0.73 | AR (1.00) | ARNR3C1PGR | |
| SCHEMBL4145604 | 0.68 | AR (0.51) | ARNR3C1 | |
| SCHEMBL1771532 | 0.65 | AR (0.48) | AR | |
| SCHEMBL5128073 | 0.65 | AR (1.00) | ARNR3C1PGR | |
| SCHEMBL1771743 | 0.64 | AR (0.48) | AR | |
| SCHEMBL5122320 | 0.64 | AR (1.00) | ARNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107372-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | LANTER JAMES C (US) | 2005-05-19 | — | — | US | disclosed |
| US-6858621-B2 | 2-(quinolonyl)-fused heterocycles as androgen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1501835-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040014743-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003090672-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014743-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | AR, NR5A1, ESRRA | AR 1/4885NR3C1 18/4885PGR 64/4885 |
| US-20050107372-A1 | 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators | AR, NR5A1, CYP19A1 | AR 1/4885NR3C1 29/4885PGR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.